Arcellx : January 2023 Corporate Presentation

Corporate Presentation

January 2023

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management's beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts contained in this presentation, including statements regarding the anticipated completion of our proposed collaboration with Kite and the proposed concurrent equity investment by Kite; the potential benefits, value, synergies and results that may be achieved through the proposed collaboration; the anticipated payments that may be received by us in connection with the collaboration, including potential milestones and royalties; our and Kite's respective rights and obligations under the transaction agreements; expectations of our ability to benefit from Kite's capabilities, including operational, manufacturing and commercialization expertise and infrastructure; expected costs and expenses to be incurred and shared with Kite; our future financial condition, results of operations, business strategy, operations, timelines and prospects; the potential of and expectations regarding our product candidates and programs; the mission, plans and objectives of management; industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "can," "contemplate," "continue," "could," "design," "estimate," "expect," "imagine," "intend," "likely," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will" or "would," or the negative of these terms or other similar expressions or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, and these statements represent our views as of the date of this presentation. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Information regarding certain risks, uncertainties and assumptions may be found in our filings with the Securities and Exchange Commission. New risk factors emerge from time to time and it is not possible for our management team to predict all risk factors or assess the impact of all factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

This presentation discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. The presentation also includes select interim and preliminary results from an ongoing clinical trial as of specific data cutoff dates. Such results should be viewed with caution as final results may differ as additional data becomes

SOLID

available. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processesTUMORS. No90%representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

This presentation also contains estimates and other statistical data made by independent parties or publicly available information, as well as other information based on our internal sources. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the accuracy or completeness of the data contained in these industry publications and other publicly available information. Accordingly, we makes no representations as to the accuracy or completeness of that data.

Arcellx Corporate Presentation | January 2023

2

Reimagining Cell Therapy

Novel Synthetic Binding Domain

Single-infusion

ddCAR and dosable,

controllable

ARC-SparX platforms

Positive Preliminary

Clinical Results

Demonstrated 100% overall response rate and deep durability in multiple myeloma Phase 1 study.

Pivotal study enrolling

+

Partnered Lead

Program

Combining potential best in class program with Kite's commercial and manufacturing expertise

Platform

Potential

ARC-SparX Phase 1 clinical trial in MM initiated in 2Q22

ARC-SparX Phase 1

clinical trial in AML/MDS

initiated in 4Q22

Built for

Success

Strong investor base

Exceptional team Wholly owned IP Well capitalized

Arcellx Corporate Presentation | January 2023

3

2022 Achievements and Future Milestones

2022 Achievements

IPO in February raising $142.3M

ddCAR- Presented Clinical Data Updates at ASCO and ASH

Raised $128.8M in upsized public offering

ddCAR- Initiated Pivotal Study

ddCAR- Partnered lead clinical program with Kite a Gilead Company

ARC-SparX - Initiated Phase 1 in ACLX-001 in MM

ARC-SparX - Initiated ACLX-002 Phase 1 clinical trial in AML/MDS

Future Milestones	Anticipated
Timing
ddCAR - Complete enrollment in Phase 2	2H23
iMMagine pivotal trial
ddCAR - Present long-term clinical and	2H23
median PFS data from Phase 1 clinical trial
ddCAR - Initiate iMMagine-2, earlier line	2H23
clinical trial
ARC-SparX - Present interim clinical data	2H23
from ACLX-001 in MM
ddCAR - Present interim data from Phase	1H24
2 pivotal trial
ddCAR- Anticipated BLA filing for the	1H25
treatment of BCMA

Arcellx Corporate Presentation | January 2023

4

Maximizing the Value of MM Opportunity with Kite Partnership

Positioned for Leadership	Global Collaboration	Long-term Value
in CAR-T Space

Presentation | January 2023

• Combining a potential best-in- class therapy with Kite's operational capabilities
• Proven manufacturing and commercial infrastructure with global cell therapy leader, Kite
• Leveraging synergies across both companies to accelerate patient access

• Co-developmentand co- commercialization of CAR-T ddBCMA with split profits in the U.S.
• Arcellx to receive low to mid-teen royalties ex-U.S.
• Arcellx and Kite to collaborate on next generation autologous and non-autologous programs incorporating ddBCMA
• Kite to have exclusive option rights to ARC-SparX programs targeting BCMA or CS1 for use in myeloma

• Arcellx to receive $225M upfront payment and $100M equity investment
• Kite will manufacture following tech transfer and bear the CMC commercial readiness costs
• Arcellx will continue to independently progress its development pipeline for new product candidates beyond myeloma
• Arcellx is well capitalized to fund operations through BLA filing

Arcellx Corporate

5